On 21 May 2026 , Lilly published the long-awaited topline results from the TRIUMPH-1 Phase 3 trial, and the data is striking: participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks , with 45.3% of patients losing 30% or more a threshold previously only achievable with bariatric surgery
Based on the results of the study, Dr
Just because we can, doesnt mean we should. Concerns about weight loss drugs have been raised before
Phase 1 and Early Development Phase 1 studies in healthy volunteers established proof-of-concept, demonstrating that retatrutide was well-tolerated and produced dose-dependent effects on appetite, food intake, and body weight with acceptable safety profiles
Excuse me while I state the obvious, but theres a very clear target demographic with GLP-1 skincare: people taking GLP-1s
But at some point I read the caption more carefully and my Spidey sense started tingling